Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $199,405 | 7 | 79.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,775 | 10 | 12.2% |
| Food and Beverage | $6,895 | 265 | 2.7% |
| Travel and Lodging | $6,371 | 22 | 2.5% |
| Consulting Fee | $4,385 | 2 | 1.7% |
| Honoraria | $3,600 | 1 | 1.4% |
| Education | $3.85 | 1 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $199,231 | 3 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $22,233 | 41 | $0 (2020) |
| AbbVie Inc. | $14,976 | 59 | $0 (2021) |
| PFIZER INC. | $7,166 | 38 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $2,905 | 10 | $0 (2022) |
| Celgene Corporation | $2,046 | 24 | $0 (2022) |
| Janssen Biotech, Inc. | $781.27 | 28 | $0 (2022) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $465.36 | 26 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $398.17 | 17 | $0 (2020) |
| UCB, Inc. | $275.93 | 11 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $2,434 | 27 | Celgene Corporation ($1,780) |
| 2021 | $1,526 | 19 | Eli Lilly and Company ($978.72) |
| 2020 | $162,553 | 41 | Eli Lilly and Company ($155,922) |
| 2019 | $43,942 | 77 | Eli Lilly and Company ($42,330) |
| 2018 | $23,006 | 76 | Merck Sharp & Dohme Corporation ($21,918) |
| 2017 | $17,975 | 68 | AbbVie, Inc. ($14,142) |
All Payment Transactions
308 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $101.00 | General |
| 12/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| 12/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 11/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $163.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $120.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $59.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $43.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 11/01/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.00 | General |
| 10/08/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 10/08/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $59.99 | General |
| Category: Neuroscience | ||||||
| 10/08/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $49.99 | General |
| Category: Neuroscience | ||||||
| 10/08/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: Neuroscience | ||||||
| 10/08/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.99 | General |
| Category: Neuroscience | ||||||
| 10/07/2022 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $315.27 | General |
| Category: Neuroscience | ||||||
| 09/30/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 09/30/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 09/30/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/30/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/29/2022 | Celgene Corporation | — | Travel and Lodging | Cash or cash equivalent | $383.13 | General |
| 06/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $181.26 | General |
| Category: Neuroscience | ||||||
| 06/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $49.97 | General |
| Category: Neuroscience | ||||||
| 06/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $49.97 | General |
| Category: Neuroscience | ||||||
| 06/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $29.96 | General |
| Category: Neuroscience | ||||||
| 06/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $29.96 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $198,252 | 2 |
| AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $978.72 | 1 |
| M16-009 | AbbVie, Inc. | $174.09 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 32 | 43 | $27,950 | $4,352 |
| 2020 | 2 | 59 | 94 | $61,850 | $9,559 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 32 | 43 | $27,950 | $4,352 | 15.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 44 | 79 | $51,350 | $7,267 | 14.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $10,500 | $2,292 | 21.8% |
About Dr. Garrett Lawlor, M.D
Dr. Garrett Lawlor, M.D is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2009. The National Provider Identifier (NPI) number assigned to this provider is 1386874972.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Garrett Lawlor, M.D has received a total of $251,435 in payments from pharmaceutical and medical device companies, with $2,434 received in 2022. These payments were reported across 308 transactions from 22 companies. The most common payment nature is "" ($199,405).
As a Medicare-enrolled provider, Lawlor has provided services to 91 Medicare beneficiaries, totaling 137 services with total Medicare billing of $13,911. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 07/17/2009
- Last Updated 03/25/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1386874972
Products in Payments
- RENFLEXIS (Biological) $17,599
- Humira (Biological) $7,137
- XELJANZ (Drug) $4,229
- ZEPOSIA (Drug) $1,479
- INFLECTRA (Biological) $826.64
- STELARA (Biological) $761.13
- Entyvio (Biological) $549.03
- XIFAXAN (Drug) $304.58
- Cimzia (Drug) $275.93
- XIFAXANIBSD (Drug) $266.20
- DIFICID (Drug) $249.21
- VIBERZI (Drug) $165.10
- Mavyret (Drug) $144.35
- LINZESS (Drug) $140.72
- HUMIRA (Biological) $134.35
- Viekira (Drug) $118.31
- ZEPATIER (Drug) $112.49
- Trulance (Drug) $91.22
- GATTEX (Drug) $60.66
- Sucraid (Drug) $31.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554